Vanda Pharmaceuticals (VNDA) Quarterly EPS earnings growth

Vanda Pharmaceuticals (VNDA) relies on exclusive patents in psychopharmacology, allowing for flexible pricing power over orphan drugs. The quarter-over-quarter EPS dynamics provided by GURU.Markets demonstrate the current metric 2.40. Stable cash flow from mature products and adherence to ESG standards in bio-development create a solid foundation for the company's long-term growth.

Vanda Pharmaceuticals Inc. (VNDA) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 11/15/2026

Financial and market metric breakdowns for Vanda Pharmaceuticals (VNDA)

- share price and consensus valuation forecast:

Stock Quotes vandapharma.com|VNDA - Average Forecast Price

- market capitalization details:

Market Capitalization Vanda Pharmaceuticals Inc.|VNDA - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Book Value per Share Vanda Pharmaceuticals|VNDA - Accounting Value of Company|Market Value to Book Value Ratio vandapharma.com|VNDA - Company Assets

- debt and liquidity details:

- earnings and valuation multiples indicators:

VNDA - Net Profit|Future Profit Vanda Pharmaceuticals|VNDA - Company Value to Net Income|Future Price to Earnings Vanda Pharmaceuticals Inc|VNDA - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Vanda Pharmaceuticals Inc.|VNDA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Vanda Pharmaceuticals|VNDA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months vandapharma.com|VNDA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Vanda Pharmaceuticals

- sales revenue and business income indicators:

VNDA - Company Sales|Projected Sales Volume Vanda Pharma|VNDA - P/S Multiple|Forward P/S Multiple Vanda Pharmaceuticals Inc.|VNDA - Revenue Growth YoY (Last 12 Months)

Initial company analysis:Vanda Pharmaceuticals

Vanda Pharmaceuticals (VNDA) occupies the niche of a developer of targeted drugs for the therapy of CNS disorders, leveraging robust R&D potential. Earnings per share dynamics reflect the efficiency of monetizing these innovations and the company's ability to create shareholder value. By analyzing the intensity of quarterly EPS growth, investors assess the rate of net income increase relative to market expectations. A positive trend confirms financial stability and the potential for payouts. The stability of this metric testifies to the fundamental strength of the biopharmaceutical business.

Key competitors